The partnership was formed as a key element of a strategic initiative for Sanwa Kagaku Kenkyusho (SKK) to target the Asian market, in step with SKK’s new medium-long term business plan and expanding presence in diabetic research.
Th alliance is expected to help SKK achieve its drug discovery goals. The business terms and details of this project were not disclosed.
Michael Hui, CEO of ChemPartner, said: “We are delighted to be entering this strategic alliance with SKK. We are proud and honored that SKK have selected ChemPartner to be one of their partners and we look forward to building a long and successful relationship between our two companies in the future.”